In 2,749 adults followed about two years, heart events hit 4.2% on the pill versus 5.0% on glargine. Gut side effects were far more common on orforglipron.
Recap by typeshit. Full story at Neurology Advisor.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
The review argues that a patient's own risk profile matters more than broad safety worries when looking at GLP-1 receptor agonists.
Johns Hopkins researchers found its early uptake curve was 4.4 times steeper than Zepbound's, and injectable Wegovy prescriptions didn't fall after the pill arrived.
Loading…